Research ArticleClinical Investigations
Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
Steve Y. Cho, Kenneth L. Gage, Ronnie C. Mease, Srinivasan Senthamizhchelvan, Daniel P. Holt, Akimosa Jeffrey-Kwanisai, Christopher J. Endres, Robert F. Dannals, George Sgouros, Martin Lodge, Mario A. Eisenberger, Ronald Rodriguez, Michael A. Carducci, Camilo Rojas, Barbara S. Slusher, Alan P. Kozikowski and Martin G. Pomper
Journal of Nuclear Medicine December 2012, 53 (12) 1883-1891; DOI: https://doi.org/10.2967/jnumed.112.104661
Steve Y. Cho
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Kenneth L. Gage
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Ronnie C. Mease
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Srinivasan Senthamizhchelvan
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Daniel P. Holt
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Akimosa Jeffrey-Kwanisai
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Christopher J. Endres
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Robert F. Dannals
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
George Sgouros
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Martin Lodge
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
Mario A. Eisenberger
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Ronald Rodriguez
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
3Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland
Michael A. Carducci
3Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland
Camilo Rojas
4Brain Sciences Institute of Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, Maryland; and
Barbara S. Slusher
4Brain Sciences Institute of Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, Maryland; and
Alan P. Kozikowski
5Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois
Martin G. Pomper
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland
2Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 53, Issue 12
December 1, 2012
Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
Steve Y. Cho, Kenneth L. Gage, Ronnie C. Mease, Srinivasan Senthamizhchelvan, Daniel P. Holt, Akimosa Jeffrey-Kwanisai, Christopher J. Endres, Robert F. Dannals, George Sgouros, Martin Lodge, Mario A. Eisenberger, Ronald Rodriguez, Michael A. Carducci, Camilo Rojas, Barbara S. Slusher, Alan P. Kozikowski, Martin G. Pomper
Journal of Nuclear Medicine Dec 2012, 53 (12) 1883-1891; DOI: 10.2967/jnumed.112.104661
Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer
Steve Y. Cho, Kenneth L. Gage, Ronnie C. Mease, Srinivasan Senthamizhchelvan, Daniel P. Holt, Akimosa Jeffrey-Kwanisai, Christopher J. Endres, Robert F. Dannals, George Sgouros, Martin Lodge, Mario A. Eisenberger, Ronald Rodriguez, Michael A. Carducci, Camilo Rojas, Barbara S. Slusher, Alan P. Kozikowski, Martin G. Pomper
Journal of Nuclear Medicine Dec 2012, 53 (12) 1883-1891; DOI: 10.2967/jnumed.112.104661
Jump to section
Related Articles
Cited By...
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of 68Ga-PSMA-11 in Patients with Prostate Cancer
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer
- Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
- Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
- Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
- Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer
- Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer
- PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
- Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT
- Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2+
- PSMA Ligands for PET Imaging of Prostate Cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
- Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
- Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted {alpha}-Particle Radiopharmaceutical Therapy
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
- 18F-Fluoride PET in the Assessment of Malignant Bone Disease
- Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
- 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer
- A Novel 111In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
- Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
- Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates
- Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
- Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer
- AEG-1 Promoter-Mediated Imaging of Prostate Cancer
- PET/MR Imaging: A Critical Appraisal